Showing 8,941 - 8,960 results of 49,729 for search '(( 50 ((teer decrease) OR (a decrease)) ) OR ( 5 ((point decrease) OR (mean decrease)) ))', query time: 1.22s Refine Results
  1. 8941

    Spline curves for assessing the association between sleep duration and constipation and related components. by Toshiaki Ohkuma (483462)

    Published 2024
    “…The circles at 4.5, 5.5, 6.5, 7.5, and 8.5 hours/day represent the points at which knots were placed. …”
  2. 8942
  3. 8943
  4. 8944
  5. 8945
  6. 8946
  7. 8947

    Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

    Published 2015
    “…The difference between the time points was marginally significant (p = 0.090), as well as the interaction between time and groups (p = 0.079).…”
  8. 8948

    Table_5_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

    Published 2020
    “…There were no significant differences in both supine and standing HRV between finishers (n = 14) and non-finishers (n = 11, mean distance 67 km). In finishers, a slower race velocity was significantly correlated with a higher decrease in parasympathetic drive during position change [larger decrease in High Frequency power normalized units (HF<sub>nu</sub>: r = −0.7, p = 0.01) and higher increase in the detrended fluctuation analysis alpha 1 index (DFA1: r = 0.6, p = 0.04)]. …”
  9. 8949

    Impact of the announcement and implementation of the UK Soft Drinks Industry Levy on sugar content, price, product size and number of available soft drinks in the UK, 2015-19: A co... by Peter Scarborough (329722)

    Published 2020
    “…We measured the impact of the SDIL on price, product size, number of soft drinks on the marketplace, and the proportion of drinks over the lower levy threshold of 5 g sugar per 100 mL.</p><p>Methods and findings</p><p>We analysed data on a total of 209,637 observations of soft drinks over 85 time points between September 2015 and February 2019, collected from the websites of the leading supermarkets in the UK. …”
  10. 8950
  11. 8951
  12. 8952

    Dataset. by Naved Alam (17227106)

    Published 2024
    “…The mean age (Standard Deviation) was 33.18 (10), and the mean DMFT score of factory workers was 2.84 (3.12). …”
  13. 8953
  14. 8954
  15. 8955
  16. 8956
  17. 8957
  18. 8958

    image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

    Published 2020
    “…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”
  19. 8959

    presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

    Published 2021
    “…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”
  20. 8960

    image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

    Published 2020
    “…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”